Cartesian Therapeutics Inc

In Stage 2 advancing, medium-term bullish structure remains intact with higher highs and rising EMAs, but terminal blow-off top and exhaustion patterns combined with overbought readings call for caution. Price is extended and requires a pullback into the rising EMAs or prior breakout zone for a favorable entry. Long-term downtrend persists as a structural headwind.

• ↑Secured $150M non-dilutive funding extends trials with minimal dilution
• ↑Analyst consensus Strong Buy with $34.57 price target (+236% upside)
• ↓Q1 net loss $1.46/sh missed estimates by 62%, straining cash